CN102274238A - Pharmaceutical composition for treating pancreatic cancer - Google Patents
Pharmaceutical composition for treating pancreatic cancer Download PDFInfo
- Publication number
- CN102274238A CN102274238A CN 201110180949 CN201110180949A CN102274238A CN 102274238 A CN102274238 A CN 102274238A CN 201110180949 CN201110180949 CN 201110180949 CN 201110180949 A CN201110180949 A CN 201110180949A CN 102274238 A CN102274238 A CN 102274238A
- Authority
- CN
- China
- Prior art keywords
- tetrahydropyrimidine
- gemcitabine
- pharmaceutical composition
- pancreatic cancer
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 12
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 208000008443 pancreatic carcinoma Diseases 0.000 title abstract description 6
- 201000002528 pancreatic cancer Diseases 0.000 title abstract 4
- 229960005277 gemcitabine Drugs 0.000 claims abstract description 33
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract description 32
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940058307 antinematodal tetrahydropyrimidine derivative Drugs 0.000 claims abstract description 13
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 6
- 150000005326 tetrahydropyrimidines Chemical class 0.000 abstract description 6
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- KIIBBJKLKFTNQO-UHFFFAOYSA-N 5-hydroxy-2-methyl-1,4,5,6-tetrahydropyrimidin-3-ium-6-carboxylate Chemical compound CC1=NCC(O)C(C(O)=O)N1 KIIBBJKLKFTNQO-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 20
- 230000000694 effects Effects 0.000 description 9
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WQXNXVUDBPYKBA-UHFFFAOYSA-N 2-Methyl-4-carboxy-3,4,5,6-tetrahydropyrimidine Chemical compound CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- BVWAOXGNDVRQSO-UHFFFAOYSA-N 3-hydroxy-2,6-dihydro-1h-pyrimidine Chemical compound ON1CNCC=C1 BVWAOXGNDVRQSO-UHFFFAOYSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241001471187 Patu Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- -1 gemcitabine compound Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating pancreatic cancer, and the pharmaceutical composition comprises gemcitabine and tetrahydropyrimidine or tetrahydropyrimidine derivatives used as active ingredients, wherein the tetrahydropyrimidine derivatives include 1,4,5,6-tetrahydro-2-methyl-5-hydroxy-4-pyrimidinecarboxylic acid and the like. The mass ratio of gemcitabine to tetrahydropyrimidine or tetrahydropyrimidine derivatives in the composition is 3:1. The inventor found in pharmacodynamic studies that the combination of gemcitabine and tetrahydropyrimidine or tetrahydropyrimidine derivatives in a certain proportion has distinct therapeutic effect on pancreatic cancer. Tetrahydropyrimidine or tetrahydropyrimidine derivatives can improve the therapeutic effect of gemcitabine on pancreatic cancer, and can reduce the toxicity of gemcitabine.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of cancer of pancreas.
Background technology
Tumor is one of common disease that threatens human health, be only second to cardiovascular disease, research about tumor has obtained bigger progress, developed the method such as various radiotherapies, chemotherapy of multiple treatment tumor, but all there are limitation in various medicines and therapy, be difficult to reach the effect of radical cure, and be prone to drug resistance and side effect.The tumor mortality rate still occupy first of the various diseases.The tool data show, existing 3,000,000 people of China in 2006 die from cancer, and tumor incidence still is in ascendant trend, and rejuvenation trend is arranged.In less than the time in 20 years, China's tumor incidence has risen 69% according to statistics, and mortality rate has risen 29.4%.Therefore, the new developing effective tumor treating medicaments of research is still the main direction of present oncotherapy.
Solid tumor is generally adopted the method for excision, but excision is bigger to patient's damage, and is difficult to guarantee that excision is clean, after tumor tissues occurred soaking into adhesion, obscure boundary excision difficulty was higher, and some cerebral tissue solid tumor excision risk is higher.Radiotherapy also is one of common method in oncotherapy, but, it is comparatively serious to injury of human, often cause patient's system to descend, prognosis mala, be difficult to bear the side effect of chemotherapy for the part patient, and radiotherapeutic effect is also unsatisfactory, and cost issues also is one of reason of its application of restriction.Therefore the Drug therapy to tumor is still the method for the most generally using.
The annual newly-increased tumor patient of China reaches 1,600,000-1,700,000 people in recent years, and sum is about 4,500,000 people.Its M ﹠ M all presents ascendant trend." the Chinese health statistics summary in 2009 " of health ministry issue shows, in the special rates of part cities and counties top ten disease death in 2008, it is the first that malignant tumor occupy, and become the No.1 killer of harm humans health.
Although there have been many antitumor drug, and have more chemical compound to be found to have antitumor action.But, most of antitumor drug are owing to lack ideal selectivity, in inhibition or killing tumor cell, human normal tissue cell also had inhibition or damaging action, thereby have a more side effect, add effect, plus cisplatin in treatment ovarian cancer or the carcinoma of testis inductive neurotoxicity of institute and the nephrotoxicity thereof etc. of bone marrow toxicity due to the cyclophosphamide chemotherapy regimen as cardiac toxicity, the cisplatin of anthracene nucleus class antitumor antibiotic amycin.Therefore, how when keeping and improving the antitumor drug curative effect, reducing its toxic action is the emphasis of antitumor drug research and development.
Gemcitabine is the class thing of deoxycytidine, belongs to cell cycle specific agents, is the choice drug of the unresectable cancer of pancreas of present clinical treatment, uses very extensive clinically.
But, because gemcitabine lacks targeting, it is extensive in each tissue distribution of health to take the back, therefore, its side effect is also more relatively, as anemia, leucocytes reduction, thrombocytopenia, liver transaminase disorder, albuminuria and hematuria, edema/peripheral edema, alopecia, drowsiness, the constipation etc. of suffering from diarrhoea.Side effect widely is the principal element of restriction gemcitabine clinical practice.
The English ectoin by name of tetrahydropyrimidine, CAS number is 96702-03-3, chemistry by name 1,4,5,6-tetrahydrochysene-2-methyl-4-pyrimidine carboxylic or 2-Methyl-1,4,5,6-tetrahydropyrimidine-4-carboxylic acid or (S)-2-methyl-1,4,5,6-tetra-hydro pyrimidine-4-carboxylic acid or 1,4,5,6-tetrahydro-2-methyl-4-pyrimidine carbonic acid is the amino acid derivativges of finding in 1985, discovered in recent years, it has certain mitigation to allergic disease, may be relevant with its moisture-keeping function.In addition tetrahydropyrimidine has been used to cosmetics, as preserving moisture or suntan lotion.
Summary of the invention
At above-mentioned prior art, the purpose of this invention is to provide a kind of pharmaceutical composition for the treatment of cancer of pancreas, a kind of specifically antineoplastic pharmaceutical compositions that contains gemcitabine and tetrahydropyrimidine or tetrahydropyrimidinederivatives derivatives.
For achieving the above object, the technical solution used in the present invention is:
A kind of treatment cancer of pancreas pharmaceutical composition is made up of gemcitabine and tetrahydropyrimidine or tetrahydropyrimidinederivatives derivatives and pharmaceutically acceptable carrier.
Described tetrahydropyrimidinederivatives derivatives is 1,4,5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic.
The mass ratio of described gemcitabine and tetrahydropyrimidine or tetrahydropyrimidinederivatives derivatives is 3:1.
When the discovery that the inventor is surprised under study for action, tetrahydropyrimidine and derivant thereof and gemcitabine were made up according to a definite proportion, tetrahydropyrimidine and derivant thereof can significantly improve the drug effect of gemcitabine, and reduced its untoward reaction.
Tetrahydropyrimidine described in the technical scheme of the present invention, English ectoine by name, CAS number is 96702-03-3, chemistry by name 1,4,5,6-tetrahydrochysene-2-methyl-4-pyrimidine carboxylic or 2-Methyl-1,4,5,6-tetrahydropyrimidine-4-carboxylic acid or (S)-2-methyl-1,4,5,6-tetra-hydro pyrimidine-4-carboxylic acid or 1,4,5,6-tetrahydro-2-methyl-4-pyrimidine carbonic acid.1,4,5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic is commonly called as the hydroxy tetrahydro pyrimidine, and this is that those skilled in the art are known.
The specific embodiment
Below in conjunction with embodiment the present invention is further explained.Should be understood that following examples only are used to explain the present invention, rather than restriction protection scope of the present invention.
The preparation of embodiment 1 tetrahydropyrimidine and gemcitabine composition tablet
It is as follows to fill a prescription:
Tetrahydropyrimidine 20g
Gemcitabine 60g
Microcrystalline Cellulose 20g
Magnesium stearate 10g
Polyvinylpyrrolidone 20g
The tetrahydropyrimidine and the gemcitabine of prescription are crossed 150 μ m sieve, and it is standby that adjuvant is crossed 180 μ m sieve; Tetrahydropyrimidine and gemcitabine are mixed with microcrystalline Cellulose, successively mix with polyvinylpyrrolidone, magnesium stearate, tabletting gets final product behind the mix homogeneously.
Embodiment 21, and 4,5, the preparation of 6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic and gemcitabine composition tablet
1,4,5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic 10g
Gemcitabine 30g
Microcrystalline Cellulose 10g
Differential silica gel 10g
Sodium lauryl sulphate 5 g
With 1,4,5 of prescription, it is standby that 6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic and gemcitabine are crossed 180 μ m sieve; With sieve 1,4,5, press large stretch ofly behind 6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic and gemcitabine and the microcrystalline Cellulose mixing, after granulate obtains smaller particles, add sodium lauryl sulphate and differential silica gel, the mixing tabletting gets final product.
Embodiment 31, and 4,5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic and gemcitabine compound injection and preparation
1,4,5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic 40g
Gemcitabine 120g
Polyethylene Glycol 150ml
Water for injection adds the injection water to 1000ml
Preparation technology:
Cillin bottle, plug are slightly washed earlier, after use through the filterable water for injection fine purifiation of 0.45 μ m microporous filter membrane qualified to visible foreign matters, dry for standby then.
In irritating, dosing adds 1,4,5 of recipe quantity, 6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic, and Polyethylene Glycol 50 ml dissolve it fully, as solution 1.
Add the gemcitabine of recipe quantity in another dosing is irritated, Polyethylene Glycol 100 ml dissolve it fully, as solution 2.
Solution 2 is merged in the adding solution 1, and 80 ℃ were heated 10 minutes, and added to the full amount of water for injection mixing after the cooling.
Embodiment 4 tetrahydropyrimidines and gemcitabine pharmaceutical composition are to pancreas in rat treatment for cancer evaluation of effect
Human pancreas cancer cell strain Patu 8988 is put into the RPMI-1640 complete medium that contains 10 % to be cultivated.The take the logarithm human pancreas cancer cell strain of trophophase is by every 5 * 10
6Individual tumor cell inoculation is set up tumor model in nude mouse axillary fossa place.
Get 60 of the nude mouses of modeling success, measure gross tumor volume, be divided into 3 groups at random, 20 every group, first group of subcutaneous injection gives normal saline; Second group of subcutaneous injection gives gemcitabine, and dosage is 2mg/kg; The 3rd group of subcutaneous injection gives embodiment the injection of 3 preparations, presses gemcitabine and calculates, and dosage is 2mg/kg.Every treated animal, administration every day 1 time, successive administration 12 days is measured gross tumor volume after the administration, calculate tumour inhibiting rate, and adds up during each treated animal administration and administration finishes mortality rate in back 10 days.
The results are shown in following table.
Respectively organize tumour inhibiting rate (%) and each treated animal mortality rate (%) after table 1 administration
| Grouping | Tumour inhibiting rate | Mortality rate |
| First group | 0 | 100 |
| Second group | 47 | 50 |
| The 3rd group | 79 | 10 |
As seen from Table 1, the compositions antitumor action of embodiment 3 preparations is significantly higher than gemcitabine, and toxicity is littler than gemcitabine, and the prompting tetrahydropyrimidine can improve the curative effect of gemcitabine and reduce the toxic action of gemcitabine.
Claims (3)
1. pharmaceutical composition for the treatment of cancer of pancreas is made up of gemcitabine and tetrahydropyrimidine or tetrahydropyrimidinederivatives derivatives and pharmaceutically acceptable carrier.
2. pharmaceutical composition according to claim 1 is characterized in that, described tetrahydropyrimidinederivatives derivatives is 1,4,5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic.
3. according to the described pharmaceutical composition of claim 1-2, it is characterized in that the mass ratio of described gemcitabine and tetrahydropyrimidine or tetrahydropyrimidinederivatives derivatives is 3:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110180949A CN102274238B (en) | 2011-06-30 | 2011-06-30 | Pharmaceutical composition for treating pancreatic cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110180949A CN102274238B (en) | 2011-06-30 | 2011-06-30 | Pharmaceutical composition for treating pancreatic cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102274238A true CN102274238A (en) | 2011-12-14 |
| CN102274238B CN102274238B (en) | 2012-10-03 |
Family
ID=45100184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110180949A Expired - Fee Related CN102274238B (en) | 2011-06-30 | 2011-06-30 | Pharmaceutical composition for treating pancreatic cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102274238B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107176937A (en) * | 2017-04-20 | 2017-09-19 | 沈阳药科大学 | α pyranone phomoneD and its preparation method and application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030114358A1 (en) * | 2000-02-14 | 2003-06-19 | Erwin Galinski | Use of compatible solutes as inhibitors of the enzymatic decomposition of macromolecular biopolymers |
| CN1878556A (en) * | 2003-09-18 | 2006-12-13 | 康宾纳特克斯公司 | Combinations of drugs for the treatment of neoplasms |
| WO2009058399A1 (en) * | 2007-10-31 | 2009-05-07 | Diffusion Pharmaceuticals Llc | A new class of therapeutics that enhance small molecule diffusion |
-
2011
- 2011-06-30 CN CN201110180949A patent/CN102274238B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030114358A1 (en) * | 2000-02-14 | 2003-06-19 | Erwin Galinski | Use of compatible solutes as inhibitors of the enzymatic decomposition of macromolecular biopolymers |
| CN1878556A (en) * | 2003-09-18 | 2006-12-13 | 康宾纳特克斯公司 | Combinations of drugs for the treatment of neoplasms |
| WO2009058399A1 (en) * | 2007-10-31 | 2009-05-07 | Diffusion Pharmaceuticals Llc | A new class of therapeutics that enhance small molecule diffusion |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107176937A (en) * | 2017-04-20 | 2017-09-19 | 沈阳药科大学 | α pyranone phomoneD and its preparation method and application |
| CN107176937B (en) * | 2017-04-20 | 2019-08-30 | 沈阳药科大学 | α-pyrone phomone D and its preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102274238B (en) | 2012-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102068474B (en) | Capparis spinosa fruit gel ointment, production method thereof, and application thereof to antirheumatic medicaments | |
| CN111228287A (en) | Application of epimedium flavone glycoside compound in preparing medicine for treating melanoma | |
| CN102274238B (en) | Pharmaceutical composition for treating pancreatic cancer | |
| CN111214475B (en) | A kind of combined drug composition for anti-double hit lymphoma and application thereof | |
| CN103893188A (en) | Application of ilexgenin A in preparation of anti-tumor medicaments | |
| CN108703968B (en) | Application of levo-stepholidine for inhibiting or treating metastatic breast cancer | |
| CN105147696A (en) | Anti-breast cancer granules combining metformin hydrochloride and gdc 0941 and a preparation method thereof | |
| CN104069194B (en) | A kind of Chinese medicine composition with antitumaous effect and its production and use | |
| CN105380956A (en) | Medicine composition which is used for treating leukemia and contains idelalisi and application | |
| CN102225067B (en) | Pharmaceutical composition for treating stomach cancer | |
| CN101422534B (en) | Radio therapy sensitization composite preparation | |
| CN104398922B (en) | A kind of Chinese medicine composition for the treatment of infantile eczema | |
| CN102240298B (en) | Pharmaceutical composition for resisting tumors | |
| CN104800216A (en) | Nitidine chloride, derivative thereof, and applications of nitidine chloride and derivative of nitidine chloride in preparing medicines used for preventing and treating dermatosis | |
| CN105267793B (en) | A kind of new application of Chinese medicine composition | |
| CN101912437B (en) | Traditional Chinese medicine composition for improving bone marrow suppression caused by radiotherapy and chemotherapy and preparation method thereof | |
| AU2021106930A4 (en) | Use of epimedium-derived flavonoid glycoside in preparation of medicine for treating melanoma | |
| CN102258526A (en) | Anticancer medicinal composition | |
| CN1994365A (en) | An anti-tumor pharmaceutical composition | |
| CN116211856B (en) | Application of small molecular compound Hesperadin in preparation of medicine for treating uveal melanoma | |
| CN103933182B (en) | One treats psoriasic Chinese medicine composition and preparation method thereof | |
| CN111419853B (en) | Cucurbitacin and ibrutinib composition for treating breast cancer | |
| CN103860561B (en) | A kind of pharmaceutical composition and application thereof preventing and treating breast carcinoma | |
| CN101181232A (en) | Marseilledinun sustained-release implantation agent for curing entity tumour | |
| CN1973852A (en) | Medicine composition containing matrine and astragaloside and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180712 Address after: 250102 A block 3302, 1 drug tower, comprehensive bonded zone, Ji'nan High-tech Zone, Shandong Patentee after: Shandong Yan Quan medicine Polytron Technologies Inc. Address before: 250101 A502 room, 5 story B, University Science and Technology Park, 750 Shun Hua Road, Ji'nan hi tech Zone, Shandong Patentee before: Shandong Hongli Lab Animal Experiment Research Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121003 |